These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Gupta AK; Lynch LE; Kogan N; Cooper EA J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):256-62. PubMed ID: 19438818 [TBL] [Abstract][Full Text] [Related]
16. Acrodermatitis continua of Hallopeau due to oral terbinafine. Nishiwaki F; Matsumura Y; Morita N; Kore-Eda S; Miyachi Y; Omoto M Br J Dermatol; 2007 Nov; 157(5):1073-4. PubMed ID: 17854368 [No Abstract] [Full Text] [Related]
17. Terbinafine as a cause of cutaneous lupus erythematosus. McKellar G; Porter D; Burden D Rheumatology (Oxford); 2004 Feb; 43(2):249. PubMed ID: 14739471 [No Abstract] [Full Text] [Related]
18. Terbinafine and fulminant hepatic failure. Agarwal K; Manas DM; Hudson M N Engl J Med; 1999 Apr; 340(16):1292-3. PubMed ID: 10215503 [No Abstract] [Full Text] [Related]
19. Oral corticosteroids did not prevent AGEP due to terbinafine. Bajaj V; Simpson N Acta Derm Venereol; 2006; 86(5):448-9. PubMed ID: 16955194 [No Abstract] [Full Text] [Related]
20. [Pharma-clinics. Drug of the month. Terbinafine (Lamisil)]. Piérard GE Rev Med Liege; 1995 Aug; 50(8):352-3. PubMed ID: 7481264 [No Abstract] [Full Text] [Related] [Next] [New Search]